Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?
Ayhan A; Taskiran C; Simsek S; Sever A Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Special Gynocologic Oncology nurses, Faculty of Medicine, Hacettepe University, Ankara, Turkey. The purpose of this study was to evaluate the effect of immediate hormone replacement therapy (HRT) on oncologic outcome of patients with endometrial cancer. The patients were recruited prospectively after extensive discussion of risks and benefits of HRT. Continuous daily regimen of 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate was initiated 4-8 weeks after surgery at first postoperative visit. The patients who had the same characteristics with the HRT group were assigned as a control group. Overall, 50 patients received HRT. There was no significant difference with respect to prognosticators between the HRT users and the control group. Seven patients (14%) stopped the use of HRT. Only two patients stopped the therapy before 24 months, and all th
